New Delhi, Aug. 1 -- Indian pharmaceutical manufacturers are preparing a two-pronged strategy to offset the impact of the soon-to-be-effective 25 per cent US tariff on Indian goods, which includes drug exports, with industry experts anticipating that the move could significantly raise medicine costs in the American market.

Girdhar Gyani, Director General of the Association of Healthcare Providers (India), has voiced concern over the financial burden the proposed US tariff would impose on both Indian exporters and American consumers.

India currently supplies around 47 per cent of the US pharmaceutical market, largely in the form of affordable generics.

"If the United States enforces this 25 per cent tariff, the cost of drug delivery in ...